Krystal Biotech price target raised to $218 from $212 at Chardan

Chardan raised the firm’s price target on Krystal Biotech (KRYS) to $218 from $212 and keeps a Buy rating on the shares after the company reported Q4 results and provided an update on the Vyjuvek launch. The company highlighted its efforts to increase awareness in patients and expand the prescriber base for Vyuvek, including holding webinars with patients and prescribers, and equipping the sales team with new promotional material emphasizing the long-term safety and efficacy of Vyjuvek, the analyst tells investors in a research note. The firm added that is rolling forward its discounted cash flow and updated its model for Q4 and FY24 financials, resulting in an increased price target